+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 54 Pages
  • May 2022
  • GlobalData
  • ID: 4282126
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • CellCentric Ltd
  • Daiichi Sankyo Co Ltd
  • Foghorn Therapeutics Inc
  • Forma Therapeutics Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights


Epizyme Inc (Epizyme) is a biopharmaceutical company that discovers, develops, and markets novel epigenetic therapies for the treatment of cancer and other diseases. The company’s marketed products include Tazverik (tazemetostat), an oral, first-in-class, small-molecule inhibitor of EZH2 for the treatment of patients with metastatic or locally advanced epithelioid sarcoma and relapsed/refractory follicular lymphoma. Its pipeline products include tazemetostat for follicular lymphoma, DLBCL, epithelioid sarcoma and prostate cancer; PRMT 1 Inhibitor (GSK3368715) for solid tumors and DLBCL; and PRMT5 (GSK3368715) for solid tumors and blood cancer. The company develops products through a proprietary drug discovery platform and collaboration with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Epizyme Inc Key Recent Developments

  • May 10, 2022: Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
  • Mar 01, 2022: Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
  • Dec 02, 2021: Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting
  • Nov 18, 2021: Epizyme Announces Updates to Its Board of Directors
  • Nov 09, 2021: Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update

Key benefits of buying this profile include:

  • You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

FEATURED COMPANIES

  • CellCentric Ltd
  • Daiichi Sankyo Co Ltd
  • Foghorn Therapeutics Inc
  • Forma Therapeutics Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson

Section 1 - About the Company
  • Epizyme Inc - Key Facts
  • Epizyme Inc - Key Employees
  • Epizyme Inc - Key Employee Biographies
  • Epizyme Inc - Major Products and Services
  • Epizyme Inc - History
  • Epizyme Inc - Company Statement
  • Epizyme Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Section 2 - Company Analysis
  • Company Overview
  • Epizyme Inc - Business Description
  • Other Break-up: Collaboration Revenue
  • Performance
  • Other Break-up: Product Revenue
  • Performance
  • R&D Overview
  • Epizyme Inc - Corporate Strategy
  • Epizyme Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Epizyme Inc - Strengths
  • Epizyme Inc - Weaknesses
  • Epizyme Inc - Opportunities
  • Epizyme Inc - Threats
  • Epizyme Inc - Key Competitors

Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Epizyme Inc, Recent Deals Summary

Section 5 - Company’s Recent Developments
  • May 10, 2022: Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
  • Mar 01, 2022: Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
  • Dec 02, 2021: Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting
  • Nov 18, 2021: Epizyme Announces Updates to Its Board of Directors
  • Nov 09, 2021: Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update
  • Nov 01, 2021: Epizyme launches in my blood online resource to empower people living with follicular lymphoma to play a proactive role in treatment-decision making
  • Aug 09, 2021: Epizyme Announces CEO Succession
  • Aug 09, 2021: Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update
  • Jun 16, 2021: Epizyme launches EZH2Now Testing Program with Quest Diagnostics for relapsed or refractory follicular lymphoma patients
  • May 06, 2021: Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results

Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact Us
  • Disclaimer

List of Tables
  • Epizyme Inc, Key Facts
  • Epizyme Inc, Key Employees
  • Epizyme Inc, Key Employee Biographies
  • Epizyme Inc, Major Products and Services
  • Epizyme Inc, History
  • Epizyme Inc, Subsidiaries
  • Epizyme Inc, Key Competitors
  • Epizyme Inc, Ratios based on current share price
  • Epizyme Inc, Annual Ratios
  • Epizyme Inc, Interim Ratios
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Epizyme Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios

List of Figures
  • Epizyme Inc, Performance Chart (2017 - 2021)
  • Epizyme Inc, Ratio Charts
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Loading
LOADING...

A selection of companies mentioned in this report includes:

  • Pfizer Inc
  • Johnson & Johnson
  • Forma Therapeutics Inc
  • Merck & Co Inc
  • Spectrum Pharmaceuticals Inc
  • Secura Bio Inc
  • Foghorn Therapeutics Inc
  • Novartis AG
  • GlaxoSmithKline Plc
  • Constellation Pharmaceuticals Inc
  • CellCentric Ltd
  • MorphoSys AG
  • Daiichi Sankyo Co Ltd